drugset
drugset / Trial / NCT05051566

A Multiple Dose Study of LY3502970 in Healthy Participants

NCT05051566 ↗

Phase 1 Completed 26 enrolled Eli Lilly and Company Quotient Sciences · collab
RandomizedCrossoverSingle-blindBasic science

Summary

The main purpose of this study is to assess how fast LY3502970 gets into the blood stream and how long it takes the body to remove it when administered in multiple oral doses as new formulation compared to that of reference LY3502970 formulation. Information about safety and tolerability will be collected. The study is open to healthy participants. The study is conducted in two parts and it will last up to about 6 months, inclusive of screening period.

Timeline

Start
2021-09-16
Primary completion
2022-04-04
Completion
2022-04-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Orforglipron Small molecule 16 mg Oral
Background Esomeprazole Small molecule 40 mg Oral

Indications

No indication recorded.